Evidence map›Paper›PMID 27200375›Full record

ArticleBioMed research international2016

Lack of an Association between Neutrophil-to-Lymphocyte Ratio and PSA Failure of Prostate Cancer Patients Who Underwent Radical Prostatectomy.

Yoko Maeda, Takashi Kawahara, Mitsuyuki Koizumi, Hiroki Ito, Yohei Kumano, Mari Ohtaka, Takuya Kondo, Taku Mochizuki, Yusuke Hattori, Jun-Ichi Teranishi and 5 more

Abstract read
In one paragraph

Article in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yoko MaedaDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Takashi KawaharaDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan; Department of Urology, Yokohama City University, Graduate School of Medicine, Yokohama 2360004, Japan.
Mitsuyuki KoizumiDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Hiroki ItoDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Yohei KumanoDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Mari OhtakaDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Takuya KondoDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Taku MochizukiDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Yusuke HattoriDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Jun-Ichi TeranishiDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Yasushi YumuraDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Yasuhide MiyoshiDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.
Masahiro YaoDepartment of Urology, Yokohama City University, Graduate School of Medicine, Yokohama 2360004, Japan.
Hiroshi MiyamotoDepartments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Hiroji UemuraDepartments of Urology and Renal Transportation, Yokohama City University Medical Center, Yokohama 2320024, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction. The neutrophil-to-lymphocyte ratio (NLR), which can be easily calculated from routine complete blood counts of the peripheral blood, has been suggested to serve as a prognostic factor for some solid malignancies. In the present study, we aimed to determine the relationship between NLR in prostate cancer patients undergoing radical prostatectomy (RP) and their prognosis. Materials and Methods. We assessed NLR in 73 men (patients) who received RP for their prostate cancer. We also performed immunohistochemistry for CD8 and CD66b in a separate set of RP specimens. Results. The median NLR in the 73 patients was 1.85. There were no significant correlations of NLR with tumor grade (p = 0.834), pathological T stage (p = 0.082), lymph node metastasis (p = 0.062), or resection margin status (p = 0.772). Based on the area under the receiver operator characteristic curve (AUROC) to predict biochemical recurrence after RP, potential NLR cut-off point was determined to be 2.88 or 3.88. However, both of these cut-off points did not precisely predict the prognosis. There were no statistically significant differences in the number of CD66b-positive neutrophils or CD8-positive lymphocytes between stromal tissues adjacent to cancer glands and stromal tissues away from cancer glands and between different grades or stages of tumors. Conclusions. There was no association between NLR and biochemical failure after prostatectomy.

Indexed as

AgedBiomarkers, TumorBlood Cell CountHumansJapanLeukocytesLymphocytesMalePrevalenceProstatectomyProstate-Specific AntigenProstatic NeoplasmsReproducibility of ResultsRetrospective StudiesSensitivity and SpecificityStatistics as TopicBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID27200375
PMCPMC4855032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.